← All trials
NCT01022749
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2009
- Primary completion
- Jul 1, 2011
- Completion date
- Jul 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 228
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- University of ParisLead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- Pierre and Marie Curie UniversityCollaborator
- Institut PasteurCollaborator
- University of ParisCollaborator
- University of ParisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.